Form 8-K - Current report:
SEC Accession No. 0001193125-22-186433
Filing Date
2022-07-01
Accepted
2022-06-30 20:59:03
Documents
19
Period of Report
2022-06-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d376547d8k.htm   iXBRL 8-K 29571
2 EX-1.1 d376547dex11.htm EX-1.1 219551
3 EX-4.1 d376547dex41.htm EX-4.1 78797
4 EX-4.2 d376547dex42.htm EX-4.2 65468
5 EX-5.1 d376547dex51.htm EX-5.1 9103
9 GRAPHIC g376547g0701000107995.jpg GRAPHIC 4217
10 GRAPHIC g376547g0701000108276.jpg GRAPHIC 2320
11 GRAPHIC g376547g0701001114973.jpg GRAPHIC 5370
  Complete submission text file 0001193125-22-186433.txt   648162

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA etnb-20220628.xsd EX-101.SCH 2850
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE etnb-20220628_lab.xml EX-101.LAB 18737
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE etnb-20220628_pre.xml EX-101.PRE 11703
13 EXTRACTED XBRL INSTANCE DOCUMENT d376547d8k_htm.xml XML 3464
Mailing Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104
Business Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104 (415) 432-9270
89bio, Inc. (Filer) CIK: 0001785173 (see all company filings)

EIN.: 831114349 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39122 | Film No.: 221059295
SIC: 2834 Pharmaceutical Preparations